CV Sciences, Inc. (CVSI) financial statements (2020 and earlier)

Company profile

Business Address 10070 BARNES CANYON ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments914151413106
Cash and cash equivalents914151413106
Restricted cash and investments 11  11
Receivables2454323
Inventory, net of allowances, customer advances and progress billings101098764
Inventory101098764
Prepaid expense11   2  
Other undisclosed current assets1888021
Total current assets:32363834252114
Noncurrent Assets
Inventory, Noncurrent   1114
Operating lease, right-of-use asset9   
Property, plant and equipment4333322
Intangible assets, net (including goodwill)7777777
Goodwill3333333
Intangible assets, net (excluding goodwill)4444444
Other noncurrent assets1111 00
Other undisclosed noncurrent assets 9441  
Total noncurrent assets:20201415111013
TOTAL ASSETS:53575248373127
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12111110432
Accounts payable2111111
Accrued liabilities1110109322
Debt1 000 1
Other undisclosed current liabilities 111   
Total current liabilities:13121211433
Noncurrent Liabilities
Long-term debt and lease obligation10      
Operating lease, liability10   
Liabilities, other than long-term debt1112111
Contract with customer, liability1  
Deferred tax liabilities, net111 11
Deferred income tax liabilities0   
Other liabilities0000   
Other undisclosed noncurrent liabilities 1045111
Total noncurrent liabilities:101166222
Total liabilities:24231818755
Stockholders' equity
Stockholders' equity attributable to parent29333431302622
Common stock0000000
Additional paid in capital71686765555453
Accumulated deficit(42)(35)(33)(34)(25)(28)(31)
Total stockholders' equity:29333431302622
TOTAL LIABILITIES AND EQUITY:53575248373127

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues9131715141412
Cost of revenue(5)(4)(5)(4)(5)(4)(3)
Gross profit:4812119109
Operating expenses(11)(10)(11)(20)(24)  
Other undisclosed operating income (loss)    17(6)(6)
Operating income (loss):(7)(2)1(9)343
Nonoperating expense
(Other Nonoperating expense)
    (0)(0)(0)
Interest and debt expense   (0)(0)(0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(7)(2)1(9)333
Other undisclosed income from continuing operations before income taxes000 000
Income (loss) from continuing operations before income taxes:(7)(2)1(9)333
Income tax expense (benefit)1(0)(0) 0(0)(0)
Net income (loss) available to common stockholders, diluted:(7)(2)1(9)333

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(7)(2)1(9)333
Comprehensive income (loss), net of tax, attributable to parent:(7)(2)1(9)333

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: